Isabella Lurje

📌In our March issue Assessment of liver graft quality during hypothermic oxygenated perfusion: The first international validation study Read it here👉journal-of-hepatology.eu/article/S0168-… #LiverTwitter

Read "Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Impacts Long-Term Outcomes After Curative-Intent Surgery for Hepatocellular Carcinoma" via open access bit.ly/3ELlRbA #livertwitter #MASLD #HCC

The EASL #LiverCancerSummit 2025 kicks off in a few days, bringing together leading experts and young investigators in Paris & online! One of the highlights? The Young Investigators Poster Tour—a dynamic ePoster session featuring research from emerging scientists in the field of liver cancer. 🗓 Date: Friday, 21 February 2025 🕑 Time: 14:00 - 14:30 CET 📅 Save the session to your calendar & stay tuned! events-apps.easl.eu/lcs2025/en-GB/… @rirmacias @AleksanderKrag @RuiCastroHD @DebbieShawcros1 @aelsharkawy75 @FabioPiscaglia

@RWTH @C_V_Schneider @AveFoundation @UniklinikAachen Congratulations! 🎈🎈🎈

Fettleber als stille Epidemie: #RWTH-Junior-Professorin Carolin Schneider @C_V_Schneider erhält den "Life Sciences Bridge Award" der Aventis Foundation @AveFoundation für ihre #Forschung auf dem Gebiet der Fettleber 👍: ➡️rwth-aachen.de/li/f/bjwvwv 📸: Uwe Dettmar #Medizin

Did you read the 17-4 Editor's Essential Reading? If so, check out the corresponding editorial, which discusses how the interleukin 33–T helper 2 cell axis promotes human liver #fibrosis. 🔗ow.ly/s7tq50R17OX 🖋️Isabella Lurje and Frank Tacke

Here we go! Looking forward to 4 jam-packed days of the latest research in #immunology at #ECI2024 @Irishimmunology @EFIS_Immunology

@C_V_Schneider Congratulations! Well-deserved 🎉

Thrilled and humbled to see my scientific contribution in digital hepatology and prevention recognized on the #ForbesUnder30 List Europe! tinyurl.com/ForbesCVS Grateful for the support and inspiration from my patients, collaborators and mentors. #Forbes #30Under30

📑 New follow-up data from the HOPE-ECD-DBD RCT looks at the long-term outcomes of #HOPE treated allografts in #liver transplantation‼️       💡Machine perfusion may reduce late-onset morbidity and improve graft survival in ECD livers‼️ #LiverTwitter journals.lww.com/hepcomm/fullte…

You can now find this as a technical note in Cytometry Part A: onlinelibrary.wiley.com/doi/full/10.10… We found some surprising differences between commercially available compensation beads 🎆

Pumps have changed transplant forever Long term follow-up after an RCT of HOPE Open access doi.org/10.1097/HC9.00… #livertwitter @HepCommJournal

First RCT data on long-term outcomes after hypothermic oxygenated machine perfusion (HOPE) in liver transplantation out now in @Hepcommjournal, showing lower incidence of late-onset complications & improved graft survival in the HOPE group. journals.lww.com/hepcomm/fullte…

@C_V_Schneider @Academics @UniklinikAachen @RWTH @KM_Schneider1 @Dhv Congratulations! 🎉

📢Feeling overwhelmed and grateful to be named German Young Scientist of the Year 2023 by @academics. Grateful for my incredible team at @UniklinikAachen @RWTH, all collaborators, mentors and especially @KM_Schneider1. Excited to receive this award in March at the @DHV Gala.

Wir suchen Verstärkung für unser Team an der @ChariteBerlin & @organ_recovery und freuen uns auf Bewerbungen. Studienkoordinatorin / Studienkoordinator (d/w/m) Chirurgische Klinik DM.219.23: Charité karriere.charite.de/stellenangebot…

🔬We analyzed graft-effluent leucocytes during hypothermic oxygenated and normothermic liver machine perfusion in this letter, now published in @Jhepatology journal-of-hepatology.eu/article/S0168-… @organ_recovery @glurje @Tacke_lab @Flt3Linda @ChariteBerlin

Die vierteilige Doku-Serie zeigt Betroffene & das medizinische Personal der #CharitéBerlin im Wettlauf gegen die Zeit. Unter ihnen: Prof. Georg Lurje, Leitender Oberarzt in der Chirurgischen Klinik am Campus Virchow-Klinikum. Copyright: rbb / DOCDAYS Productions. @glurje

⌛ Every 30 seconds, we lose someone to viral hepatitis, causing 1.34 million deaths worldwide annually. It is the leading cause of primary liver cancer, making it crucial to act against this silent killer ☠️ . Read more! 🔗 easl.eu/news/whd2023/ @EASLedu @EASLEUAffairs

📍Vienna Airport So excited to be here! #EASLCongress

🌍Today is International #NASHDay! At EASL, we are joining @globalliver to raise awareness about #NASH! Explore the resources to learn about relevant #NASH topics – for both patients & clinicians. 👉international-nash-day.com/materials/ 👉Learn more: nash-day.com #StepUpforNASH

What are the mechanisms of fibrosis across organs and disease etiologies? 💡Our latest review examines the underlying processes and resulting therapeutic opportunities. @ILurje authors.elsevier.com/a/1h7z%7EMMSm4…